natgillin/translations-raw huggingface dataset:
The blood circulation in the limb is then replaced by the ‘perfusion' of a special liquid and the limb is warmed to a temperature of between 38 and 39°C. 
Krvni obtok v okončini nato nadomesti „perfuzija“ (pretok) posebne tekočine, pri čemer okončino ogrevamo na temperaturo med 38 in 39 °C.
Other side effects seen very commonly (in more than 1 patient in 10) are infection, cardiac arrhythmia (unstable heartbeat), nausea (feeling sick), vomiting, liver damage, fatigue (tiredness), chills, pain in the limb, nerve injury, skin reactions, oedema (swelling) and wound infection. 
Drugi zelo pogosti neželeni učinki (pri več kot 1 bolniku izmed 10) so okužba, srčna aritmija (neenakomerno bitje srca), navzeja (slabost), bruhanje, okvara jeter, utrujenost, mrzlica, bolečina v okončini, poškodba živca, kožne reakcije, edemi (otekline) in okužba ran.
The active substance in Beromun, tasonermin, is produced by a method known as ‘recombinant DNA technology': it is made by bacteria that have received a gene (DNA), which makes them able to produce TNFα. 
Zdravilno učinkovino v zdravilu Beromun, tasonermin, proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK), s katerim lahko tvori TNFα.
Beromun should not be used in people who may be hypersensitive (allergic) to tasonermin or any of the other ingredients. 
Zdravila Beromun ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) tasonermin ali katero koli drugo sestavino zdravila.
Most patients taking Beromun experience fever, which is usually mild to moderate. 
Večina bolnikov, ki prejme zdravilo Beromun, dobi vročino, ki je navadno blaga do zmerna.
Melphalan is given during the same operation over 60 minutes, beginning 30 minutes after the start of the Beromun perfusion, when the temperature should be increased to 39 to 40°C. 
Med istim postopkom, 30 minut po začetku perfuzije z zdravilom Beromun, se doda melfalan v trajanju 60 minut, pri čemer je treba temperaturo povečati na 39 do 40 °C.
Why has Beromun been approved? 
Zakaj je bilo zdravilo Beromun odobreno?
It must not be used in patients with significant cardiovascular (heart and blood vessel) disease, severe lung disease, a recent or active stomach ulcer, severe ascites (fluid accumulation in the abdomen), blood disorders, kidney or liver disease, or hypercalcaemia (high blood calcium levels), or in women who are pregnant or breast-feeding. 
Ne smejo ga uporabljati bolniki z večjo srčnožilno boleznijo, hudo boleznijo pljuč, nedavno ali aktivno želodčno razjedo, hudim ascitesom (nabiranjem tekočine v trebušni votlini), krvnimi motnjami, obolenjem ledvic ali jeter ali hiperkalcemijo (visokimi ravnmi kalcija v krvi) ter ženske, ki so noseče ali dojijo.
Before Beromun is given, the limb is first isolated: while the patient is under general anaesthetic, a tight band is placed around the top of the limb to isolate its blood supply and prevent the medicine reaching the rest of the body. 
Pred dajanjem zdravila Beromun je treba najprej izolirati okončino: medtem ko je bolnik v splošni anesteziji, se okoli zgornjega dela okončine zaveže tesen trak, ki prekine dotok krvi in preprečuje, da bi zdravilo prešlo v preostalo telo.
Beromun must not be used in patients who cannot receive melphalan or who cannot undergo ILP. 
Zdravila Beromun ne smejo uporabljati bolniki, ki ne smejo prejemati melfalana ali pri katerih se izolirana perfuzija okončine ne sme izvesti.
Beromun is used in patients with soft tissue sarcoma (a type of cancer) of the limb (arm or leg), together with melphalan (an anticancer medicine), using a technique called ‘isolated limb perfusion' (ILP): both medicines are injected into the limb while the blood circulation in the limb is kept isolated (cut off) from the rest of the body. 
Zdravilo Beromun se uporablja pri bolnikih s sarkomom mehkega tkiva (vrsto raka) okončin (roke ali noge) v kombinaciji z melfalanom (zdravilom proti raku), pri čemer se uporablja tehnika, imenovana „izolirana perfuzija okončine“: obe zdravili se injicirata v okončino, pri čemer je krvni obtok v tej okončini izoliran (ločen) od preostalega telesa.
For a more complete list of the side effects reported with Beromun, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Beromun, glejte navodilo za uporabo.
The full EPAR for Beromun can be found here. 
Celotno javno poročilo o oceni zdravila (EPAR) za zdravilo Beromun je na voljo tukaj.
The Committee for Medicinal Products for Human Use (CHMP) decided that Beromun's benefits are greater than its risks as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic ILP. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Beromun kot pomožni ukrep ob poznejši kirurški odstranitvi tumorja, s katerim preprečimo ali odložimo amputacijo, ali pri paliativnem zdravljenju neoperabilnih sarkomov v mehkem tkivu okončin v kombinaciji z melfalanom z blago hipertermično izolirano perfuzijo okončine večje od z njim povezanih tveganj.
See the Summary of Product Characteristics (also part of the EPAR) for the full list of restrictions. 
Za celoten seznam omejitev glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
Beromun is a powder and solvent that are made up into a solution for infusion. 
Zdravilo Beromun je prašek in vehikel za pripravo raztopine za infundiranje.
What is Beromun used for? 
Za kaj se zdravilo Beromun uporablja?
Beromun treatment should only be carried out in special centres by surgical teams who have experience in the treatment of this type of cancer and ILP. 
Zdravljenje z zdravilom Beromun smejo izvajati samo kirurške ekipe, ki imajo izkušnje z zdravljenjem te vrste raka in s postopkom izolirane perfuzije okončin, in sicer v specialističnih centrih.
What is Beromun? 
Kaj je zdravilo Beromun?
How has Beromun been studied? 
Kako je bilo zdravilo Beromun raziskano?
The dose of melphalan depends on the size of the arm or leg. At the end of the 90-minute procedure, the medicines are flushed out of the limb using a suitable fluid. 
Ob koncu tega 90-minutnega postopka se zdravili s primerno tekočino izpereta iz okončine.
How is Beromun used? 
Kako se zdravilo Beromun uporablja?
How does Beromun work? 
Kako zdravilo Beromun deluje?
2 vials + 2 syringes 
2 viali + 2 injekcijski brizgi
1 vial + 1 syringe 
1 viala + 1 injekcijska brizga
Packaging Content (concentration) 
Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina vsebina (koncentracija)
The main measure of effectiveness was response to treatment. 
Glavno merilo učinkovitosti je bil odziv na zdravljenje.
What measures are being taken to ensure the safe and effective use of Besponsa? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Besponsa?
What is Besponsa and what is it used for? 
Kaj je zdravilo Besponsa in za kaj se uporablja?
An analysis of the first 218 patients treated showed that after at least 2 cycles of treatment, 81% (88 out of 109) of patients receiving Besponsa responded to treatment compared with 29% (32 out of 109) of patients receiving other chemotherapy. 
Analiza prvih 218 zdravljenih bolnikov je pokazala, da se je po vsaj dveh ciklih zdravljenja na zdravljenje odzvalo 81 % (88 od 109) bolnikov, ki so prejemali zdravilo Besponsa, v primerjavi z 29 % (32 od 109) bolnikov, ki so prejemali drugo kemoterapijo.
What benefits of Besponsa have been shown in studies? 
Kakšne koristi je zdravilo Besponsa izkazalo v študijah?
The infusions are given on days 1, 8 and 15 of a 3 or 4 week treatment cycle. 
Infuzije se dajejo 1., 8. in 15. dan tri- ali štiritedenskega cikla zdravljenja.
It is not intended to provide practical advice on how to use Besponsa. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Besponsa's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Besponsa večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Besponsa is given as an infusion (drip) into a vein lasting for at least one hour. 
Zdravilo Besponsa se daje kot (kapalna) infuzija v veno v trajanju vsaj ene ure.
The summary of the opinion of the Committee for Orphan Medicinal Products for Besponsa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Besponsa je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
This is a summary of the European public assessment report (EPAR) for Besponsa. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Besponsa.
Why is Besponsa approved? 
Zakaj je bilo zdravilo Besponsa odobreno?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Besponsa have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Besponsa upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
What are the risks associated with Besponsa? 
Kakšna tveganja so povezana z zdravilom Besponsa?
With regard to safety, the side effects with Besponsa are similar to those of other chemotherapy medicines and can usually be managed by dose reduction or treatment interruption. 
Kar zadeva varnost, so neželeni učinki zdravila Besponsa podobni učinkom drugih kemoterapevtskih zdravil in se jih običajno lahko obvlada z zmanjševanjem odmerka ali prekinitvijo zdravljenja.
In patients who do not respond to treatment, Besponsa should be stopped after 3 cycles. 
Pri bolnikih, ki se na zdravljenje ne odzivajo, je treba zdravljenje po treh ciklih ustaviti.
For more information about treatment with Besponsa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Besponsa preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Besponsa is used on its own in adults whose cancer has come back or did not respond to previous treatment. 
Zdravilo Besponsa se samostojno uporablja pri odraslih, pri katerih se je rak ponovil ali ki se na prejšnje zdravljenje niso odzvali.
The full EPAR for Besponsa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Besponsa je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Because the number of patients with B-cell precursor ALL is low, the disease is considered ‘rare', and Besponsa was designated an ‘orphan medicine' (a medicine used in rare diseases) on 7 June 2013. 
Ker je bolnikov s prekurzorsko B-celično ALL malo, velja ta bolezen za redko, zato je bilo zdravilo Besponsa 7. junija 2013 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Patients whose treatment works well, but who are not going to receive a stem cell transplant, may receive up to a maximum of 6 cycles of treatment. 
Bolniki, pri katerih je zdravljenje učinkovito, vendar pri njih matične celice ne bodo presajene, lahko prejmejo do največ 6 ciklov zdravljenja.
Patients in whom Besponsa works well should receive 2 or 3 cycles, after which they can have a stem cell transplant to replace their bone marrow, the only curative treatment. 
Bolniki, pri katerih je zdravilo Besponsa učinkovito, morajo prejeti dva ali tri cikle, čemur lahko sledi presaditev matičnih celic za zamenjavo kostnega mozga, kar je edino kurativno zdravljenje.
The most common side effects with Besponsa (which may affect more than 1 in 5 people) are thrombocytopenia (low blood platelet counts), neutropenia and leucopenia (low white blood cell counts), infection, anaemia (low red blood cell counts), tiredness, haemorrhage (bleeding), fever, nausea (feeling sick), headache, febrile neutropenia (low white cell count with fever), abdominal pain (stomach ache), increased levels of liver enzymes called transaminases and gammaglutamyltransferase, and hyperbilirubinaemia (high blood levels of bilirubin, a breakdown product of red blood cells). 
Najpogostejši neželeni učinki zdravila Besponsa (ki se lahko pojavijo pri več kot 1 bolniku od 5) so trombocitopenija (nizko število krvnih ploščic), nevtropenija in levkopenija (nizko število belih krvnih celic), okužba, anemija (nizko število rdečih krvnih celic), utrujenost, krvavitev, zvišana telesna temperatura, navzeja (siljenje na bruhanje), glavobol, febrilna nevtropenija (nizko število belih krvnih celic in povišana telesna temperatura), bolečine v trebuhu, zvišane ravni jetrnih encimov (transaminaz in gama-glutamiltransferaze) ter hiperbilirubinemija (visoke ravni bilirubina, razgradnega produkta rdečih krvnih celic).
Besponsa is a cancer medicine used to treat a type of blood cancer which affects B cells (a type of white blood cells) called B-cell precursor acute lymphoblastic leukaemia (ALL). 
Zdravilo Besponsa je zdravilo proti raku, ki se uporablja za zdravljenje krvnega raka, ki prizadene celice B (vrsta belih krvnih celic) in se imenuje prekurzorska B-celična akutna limfoblastna levkemija (ALL).
For the full list of all side effects and restrictions reported with Besponsa, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev, o katerih so poročali pri uporabi zdravila Besponsa, glejte navodilo za uporabo.
Other information aboutBesponsa 
Druge informacije o zdravilu Besponsa
Besponsa can only be obtained with a prescription, and treatment should be given under the supervision of a doctor who has experience in the use of cancer treatments. 
Predpisovanje in izdaja zdravila Besponsa je le na recept, zdravljenje z njim pa se sme uvesti in izvajati samo pod nadzorom zdravnika z izkušnjami z zdravljenjem raka.
For practical information about using Besponsa, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Besponsa naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The most serious side effects are infection, febrile neutropenia, haemorrhage, abdominal pain, fever, tiredness and veno-occlusive liver disease/sinusoidal obstruction syndrome (VOD/SOS, a serious liver disease). 
Najresnejši neželeni učinki so okužba, febrilna nevtropenija, krvavitev, bolečine v trebuhu, vročina, utrujenost in venookluzivna bolezen jeter/sindrom obstrukcije sinusoidov (VOD/SOS, resna bolezen jeter).
This means that patients' have a particular protein (CD22) on the surface of their white blood cells. 
To pomeni, da imajo bolniki na površini belih krvnih celic posebno beljakovino (CD22).
How is Besponsa used? 
Kako se zdravilo Besponsa uporablja?
The active substance in Besponsa, inotuzumab ozogamicin, is a monoclonal antibody (a type of protein) that has been linked to a small molecule, N-acetyl-gamma-calicheamicin dimethylhydrazide. 
Zdravilna učinkovina v zdravilu Besponsa, inotuzumab ozogamicin, je monoklonsko protitelo (vrsta beljakovine), ki je vezano na majhno molekulo, N-acetil-gama-kaliheamicin dimetilhidrazid.
The CHMP considered that although there have been recent advances in the treatment of B-cell precursor ALL, treatment options for patients remain limited. 
Odbor CHMP je ocenil, da ostajajo možnosti zdravljenja prekurzorske B-celične ALL kljub nedavnemu napredku omejene.
In patients who have a type of chromosome known as Philadelphia-chromosome, treatment with a cancer medicine called a tyrosine kinase inhibitor should have been tried before starting Besponsa. 
Pri bolnikih z vrsto kromosoma, imenovano kromosom Philadelphia, je treba pred začetkom zdravljenja z zdravilom Besponsa poskusiti z zdravljenjem z zdravilom proti raku, imenovanim zaviralec tirozin-kinaze.
Besponsa must not be used in patients who have VOD/SOS or have had severe VOD/SOS or have other serious liver diseases. 
Pri bolnikih, ki imajo VOD/SOS ali so imeli resno VOD/SOS ali drugo resno bolezen jeter, se zdravila Besponsa ne sme uporabljati.
Patients were considered to have responded if they had no remaining cancerous B cells in their blood and bone marrow after treatment. 
Pri bolnikih je bil odziv ugotovljen, če po zdravljenju v krvi in kostnem mozgu niso imeli rakavih celic B.
Patients who responded to treatment could proceed to have a stem cell transplant. 
Bolniki, ki so sodelovali v zdravljenju, so lahko prejeli presadek matičnih celic.
The main study showed that Besponsa was better than other commonly used chemotherapy medicines at inducing a response in patients and allowing them to have a curative stem cell transplant. 
Glavna študija je pokazala, da v primerjavi z drugimi pogosto uporabljanimi kemoterapevtskimi zdravili zdravilo Besponsa pri bolnikih bolje inducira odziv in omogoči kurativno zdravljenje z matičnimi celicami.
Besponsa is only used in patients with ‘CD22-positive B-cell precursor ALL'. 
Zdravilo Besponsa se uporablja samo pri bolnikih s prekurzorsko B-celično ALL, pozitivno na CD22.
Besponsa contains the active substance inotuzumab ozogamicin. 
Zdravilo Besponsa vsebuje zdravilno učinkovino inotuzumab ozogamicin.
Besponsa was shown to be more effective than other chemotherapy (medicines to treat cancer) in one main study involving 326 adults with CD22-positive B-cell precursor ALL, which had come back or had not responded to previous treatment. 
Zdravilo Besponsa se je v glavni študiji, v katero je bilo vključenih 326 odraslih s prekurzorsko Bcelično ALL, pri katerih je prišlo do ponovitve bolezni ali ki se niso odzvali na predhodno zdravljenje, pokazalo kot učinkovitejše od druge kemoterapije (zdravil za zdravljenje raka).
Once attached, the medicine is taken up by the cell where calicheamicin becomes active, causing breaks in the cell's DNA and thereby killing the cancer cell. 
Monoklonsko telo je bilo zasnovano, da prepozna beljakovino CD22 in se veže nanjo na rakavih celicah B. Po vezavi zdravilo vstopi v celico, kjer se kaliheamicin aktivira in povzroči prekinitev celične DNK ter s tem uniči rakavo celico.
The doctor may interrupt treatment or reduce the dose, if the patient develops certain serious side effects. 
Če se pri bolniku pojavijo nekateri resni neželeni učinki, bo zdravnik morda moral začasno prekiniti zdravljenje oziroma zmanjšati odmerek.
How does Besponsa work? 
Kako zdravilo Besponsa deluje?
3 bottles 
3 stekleničke
Invented name Strength Pharmaceutical form Route of administration Packaging 
Številka EU Izmišljeno ime Jakost
EU Number 
Vsebina
Strength Pharmaceutical Form 
ime jakost farmacevtska oblika pot uporabe ovojnina velikost pakiranja
This summary was last updated in November 2012. 
Povzetek je bil nazadnje posodobljen novembra 2012.
This medicine is the same as Axura, which is already authorised in the European Union (EU). 
To zdravilo je enako zdravilu Axura, ki je že odobreno v Evropski uniji (EU).
Memantine Merz should be given once a day, at the same time every day. 
Zdravilo Memantine Merz se daje enkrat dnevno, vsak dan ob istem času.
The European Commission granted a marketing authorisation valid throughout the European Union for Memantine Merz on 22 November 2012. 
Evropska komisija je dovoljenje za promet z zdravilom Memantine Merz, veljavno po vsej Evropski uniji, odobrila dne 22. novembra 2012.
To prevent side effects, the dose of Memantine Merz is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day. 
Da se preprečijo neželeni učinki, se odmerek zdravila Memantine Merz v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg, drugi teden 10 mg, tretji teden pa 15 mg. Od četrtega tedna naprej je priporočeni vzdrževalni odmerek 20 mg enkrat dnevno.
The full EPAR for Memantine Merz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Memantine Merz je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The most common side effects with Memantine Merz (seen in between 1 and 10 patients in 100) are somnolence (sleepiness), dizziness, balance disorders, hypertension (high blood pressure), dyspnoea (difficulty breathing), constipation, headache, raised liver function test results and drug hypersensitivity (allergy to the medicine). 
Najpogostejši neželeni učinki zdravila Memantine Merz (opaženi pri 1 do 10 bolnikih od 100) so somnolenca (zaspanost), omotica, motnje ravnotežja, hipertenzija (visok krvni tlak), dispneja (oteženo dihanje), zaprtje, glavobol, povišane vrednosti jetrnih funkcijskih testov in preobčutljivost (alergija na zdravilo).
This is a summary of the European public assessment report (EPAR) for Memantine Merz. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Memantine Merz.
For more information about treatment with Memantine Merz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Memantine Merz preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The CHMP decided that Memantine Merz's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Memantine Merz večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Memantine Merz has been studied in three main studies including a total of 1,125 patients with Alzheimer's disease, some of whom had taken other medicines for their disease in the past. 
Zdravilo Memantine Merz so proučevali v treh glavnih študijah, ki so vključevale skupno 1 125 bolnikov z Alzheimerjevo boleznijo, pri čemer so nekateri izmed njih v preteklosti prejemali druga zdravila za zdravljenje te bolezni.
The tolerance and dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing treatment with Memantine Merz should be re-assessed on a regular basis. 
Prenašanje in odmerek zdravila je treba oceniti v 3 mesecih od začetka zdravljenja, od takrat naprej pa je treba koristi zdravljenja z zdravilom Memantine Merz ponovno ocenjevati v rednih intervalih.
However, when these results were considered along with those of the three additional studies, it was noted that the effect of Memantine Merz was smaller in patients with mild disease. 
Vendar pa je primerjava teh rezultatov z rezultati treh dodatnih študij pokazala, da je bil učinek zdravila Memantine Merz manjši pri bolnikih z blago boleznijo.
Treatment should only be started if a caregiver is available who will regularly monitor the use of Memantine Merz by the patient. 
Zdravljenje se sme uvesti samo, če je na voljo negovalec, ki bo redno spremljal bolnikovo jemanje zdravila Memantine Merz.
Memantine Merz is used to treat patients with moderate to severe Alzheimer's disease. 
Zdravilo Memantine Merz se uporablja za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Memantine Merz was more effective than placebo at controlling the symptoms of Alzheimer's disease. 
Zdravilo Memantine Merz je bilo pri nadzorovanju simptomov Alzheimerjeve bolezni učinkovitejše od placeba.
Memantine Merz was compared with placebo (a dummy treatment) over 24 to 28 weeks. 
Zdravilo Memantine Merz so primerjali s placebom (zdravilom brez zdravilne učinkovine) v obdobju 24 do 28 tednov.